Richa Sharma/X
Sep 3, 2025, 12:48
Richa Sharma Shares ARCADIA Post-Hoc Findings: Apixaban Prevents Recurrent Stroke in ESUS Patients with LV Dysfunction
Richa Sharma, Associate Professor of Neurology at Yale School of Medicine, has shared a post on X:
“Lower risk of recurrent stroke among patients with ESUS and left ventricular dysfunction randomized to apixaban in the ARCADIA trial in our post-hoc analysis.”
Title: Lower risk of recurrent stroke among patients with ESUS and left ventricular dysfunction randomized to apixaban in the ARCADIA trial in our post-hoc analysis.
Authors: Richa Sharma, Dinesh Jillella, Cenai Zhang, Mitchell S.V. Elkind, Hooman Kamel, Marco R. Di Tullio, Richard A. Kronmal, Balaji Krishnaiah, Shadi Yaghi, W.T. Longstreth Jr, David Tirschwell, Alexander Merkler, Fadi Nahab
Read the full article here.
Find similar posts on Hemostasis Today.
-
Nov 15, 2025, 12:24Thomas Reiser: Can AI Keep Up with Thrombosis Specialists?
-
Nov 15, 2025, 12:13Michael Makris on Immediate Suspension of Use of Plasma Derived FIX Concentrates in Punjab
-
Nov 15, 2025, 09:32Tushar Pandey: Hounoured to Be Part of Hematocon 2025
-
Nov 15, 2025, 09:11Lisa Murphy invites You to Join Her at Stroke Foundation’s Run4Stroke Marathon
-
Nov 15, 2025, 08:56Ahmed Bennis on Potential Use of P2Y12 Inhibitors as Safer Alternative in Monotherapy
-
Nov 15, 2025, 08:39Marika Nöjd: Donating Blood is An Easy Way to Do Good!
-
Nov 15, 2025, 08:19Joseph Caprini Released His UIP 2025 Session on VTE Recurrence Risk
-
Nov 15, 2025, 07:14Paul Bolaji Invites You to ”Thrombolytic Therapy in Acute Stroke in African Patients” Seminar
-
Nov 15, 2025, 07:03Carla Goulart Peron Explores The Role of Technology and Collaboration in Global Stroke Action